Anna López Ferrer, MD, PhD | Spain
2026
Anna
López Ferrer
,
MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona
,
Spain
IPC Councilor
PURE 4 for Psoriatic Arthritis Screening
Featured Experts
Related Resources
What's New
Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice
A new IPC paper in JAAD presents five priorities for improving metabolic screening, advancing GLP-1 research in the context of psoriasis, and defining the dermatologist’s role in managing cardiometabolic risk in psoriasis patients.
Wednesday, July 29, 2026
Challenging Patient Interactions: What’s Really Behind the ‘Difficult’ Label — A Conversation with Dr. John Koo
IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
Monday, July 27, 2026
Global and Collaborative Research in Psoriasis: IPC Fellows Research Class #1 Recordings
Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.
Wednesday, July 15, 2026
New in the IPC Resource Library: Research Skills
The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.
Thursday, July 13, 2026
A New Genetic Clue in Psoriasis: What the ADAR1 Discovery Means
Rare ADAR1 gene mutations drive a distinct, interferon-fueled psoriasis subtype, and it responds to JAK1 and TYK2 inhibitors rather than standard IL-17/IL-23 biologics.
Wednesday, July 15, 2026
New Take Tens on Psoriatic Arthritis
IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.
IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.